Monoclonal Antibodies Market Expected to Reach $390.58 Billion by 2030

 Monoclonal antibodies result from single type of immune cell, each a clone of single parent cell. These monoclonal antibodies are utilized in immunotherapy for the treatment of several chronic diseases such as Multiple sclerosis, cancer, cardiovascular diseases, and other. Monoclonal antibodies inhibit & target with exploit of a receptor that is involved in the development of the disease that is being treated. The monoclonal antibodies are developed from sources such as murine, chimeric, humanized, and human. The global monoclonal antibodies market size was valued at $146,642 million in 2020, and is projected to reach $390,582 million by 2030, registering a CAGR of 10.2% from 2021 to 2030.

► Don’t Miss Out “Download Your Exclusive Sample PDF Report” Now:
https://www.alliedmarketresearch.com/monoclonal-antibodies-market-A11789

Rise in prevalence of cancer and other chronic diseases, increase in R&D activities in genomics along with surge in demand for technologically advanced genetic platforms, and rise in patient awareness toward applications of monoclonal antibodies (mAb) therapy are the major factors that boost the growth of the market. In addition, increase in number of initiatives and enhanced investments from governments for the overall R&D of monoclonal antibodies, rise in number of product approvals, surge in demand for personalized medicine, and increase in number of pharmaceutical & biopharmaceutical companies are other factors that further drive the growth of the market.

However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. From 2020, five monoclonal antibodies (mAbs) been developed and got an Emergency Use Authorization (EUA) by the U.S. and South Korea regulatory agencies for the treatment of COVID-19.

Moreover, several additional regulatory agencies are evaluating monoclonal antibodies in phase 3 clinical trials or currently looking for a EUA. Monoclonal antibodies (mAbs) in development for COVID-19 were discovered from SARS-CoV-immune donors (VIR-7831 and ADG2), SARS-CoV-2-immune donors, and wild-type mice (ABBV-2B04) or immunized humanized immunoglobulin mice (REGN10933 & ABBV-47D11). Thus, increase in demand for monoclonal antibodies therapeutics against COVID-19 is anticipated to drive the monoclonal antibodies market during the forecast period.

The monoclonal antibodies market is segmented on the basis of source, indication, end user, and region.

On the basis of source, the market is categorized into murine, chimeric, humanized, and human. The human segment dominated the global monoclonal antibodies market in 2020, and is anticipated to continue this trend during the forecast period. Key factors, such as increase in government support in infection control & management, and increase in number of product approvals, drive the growth of the market. In addition, employment of advanced genetic engineering technology, rise in integration of advanced technology such as phage or yeast display, and transgenic mice for humanized monoclonal antibodies generation, and increase in usage of monoclonal antibodies for treatment of various chronic diseases further drive the growth of the monoclonal antibodies market.


Comments

Post a Comment

Popular posts from this blog

Global Carrier Screening Market Poised for Significant Growth as Genetic Health Awareness Rises

 A new in-depth market analysis indicates substantial growth within the global Carrier Screening Market . Illustratively, the market was valued at approximately $1.8 billion in 2023 and is projected to reach an estimated $4.5 billion by 2033 , demonstrating a Compound Annual Growth Rate (CAGR) of approximately 9.5% from 2024 to 2033. This robust expansion is driven by increasing public awareness of genetic health, advancements in screening technologies, and the growing emphasis on proactive reproductive planning and preventative healthcare. ► Don’t Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/request-sample/A11271 Carrier screening is a crucial genetic test performed on individuals who do not show symptoms of a genetic disorder but may carry a gene mutation that could be passed on to their children. This testing is increasingly recommended for individuals or couples planning a family to assess their risk of having a child with a s...
Read more

Sterilization Services Market to Reach $5.59 Billion, Globally, by 2030 at 5.1% CAGR

Image
 Allied Market Research published a report, titled, “ Sterilization Services Market by Method (Ethylene Oxide (ETO) Sterilization, Gamma Sterilization, E-beam Sterilization, and Other Methods), Mode of Delivery (Off-site Sterilization Services and On-Site Sterilization Services), and End User (Hospitals & Clinics, Pharmaceutical & Medical Device Companies, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030.” According to the report, the global sterilization services industry was estimated at $3.38 billion in 2020, and is anticipated to hit $5.59 billion by 2030, registering a CAGR of 5.1% from 2021 to 2030. Download Report Summary- https://www.alliedmarketresearch.com/request-sample/7878 Drivers, restraints, and opportunities- Rise in the prevalence of hospital-acquired infections (HAIs), upsurge in likelihood of epidemic or pandemic outbreaks, increase in number of surgical procedures across the globe, and augmenting use of E-beam sterilization dri...
Read more

Ultrasound Probe Disinfection Market: Growing at a CAGR of 12.4%

 The global ultrasound probe disinfection market is experiencing a period of significant expansion, driven by a confluence of factors aimed at enhancing patient safety and reducing healthcare-associated infections. Valued at an estimated $0.6 billion in 2023, the market is on a robust growth trajectory, with projections indicating it will more than double to reach $1.8 billion by 2033. This impressive growth is underpinned by a strong Compound Annual Growth Rate (CAGR) of 12.4% from 2024 to 2033, reflecting the increasing importance of infection control within modern medical practices. ► Don’t Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/ultrasound-probe-disinfection-market-A09154 A primary catalyst for this market’s growth is the escalating use of ultrasound imaging across a wide range of diagnostic and therapeutic applications. As ultrasound technology becomes more versatile and commonplace, the need for effective and reliable dis...
Read more